# Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

> **NCT00693004** · PHASE2 · TERMINATED · sponsor: **Epix Pharmaceuticals, Inc.** · enrollment: 236 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** PRX-03140
- **DRUG:** Donepezil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00693004
- **Lead sponsor:** Epix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2010-01
- **Final completion:** —
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2009-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693004, "Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00693004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*